Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man

C. G. Frondoza, S. M. Trivedi, Richard L Humphrey, J. C. Goble

Research output: Contribution to journalArticle

Abstract

[6-14C]arginine, injected intraperitoneally into normal rats, was cleared from the plasma with biphasic decay kinetics. Urinary excretion was efficient (32% of the 25-μCi dose within the first 24 hr) with no preferential tissue retention. In mice, the effective duration of the radiotracer's availability for protein biosynthesis was less than 30 min. When the tracer was administered i.v. to patients with multiple myeloma, it was similarly cleared from the plasma with biphasic kinetics, and was excreted rapidly in the urine (22% of the dose within the first 24 hr). In patients, the guanido-tagged arginine labeled only tumor M component, and the labeling was most intense in patients who had far advanced disease. Estimated radiation dose to humans from a 100-μCi injection was 10 mrads. These studies demonstrate the feasibility of in vivo labeling with [6-14C]arginine, with minimal radiation hazard, thus providing a simple, sensitive, and specific method for monitoring the synthesis of the plasmacytoma M component in patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalJournal of Nuclear Medicine
Volume21
Issue number1
StatePublished - 1980

Fingerprint

Arginine
Myeloma Proteins
Multiple Myeloma
Radiation
Plasmacytoma
Feasibility Studies
Protein Biosynthesis
Urine
Injections
Neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Frondoza, C. G., Trivedi, S. M., Humphrey, R. L., & Goble, J. C. (1980). Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man. Journal of Nuclear Medicine, 21(1), 52-58.

Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man. / Frondoza, C. G.; Trivedi, S. M.; Humphrey, Richard L; Goble, J. C.

In: Journal of Nuclear Medicine, Vol. 21, No. 1, 1980, p. 52-58.

Research output: Contribution to journalArticle

Frondoza, CG, Trivedi, SM, Humphrey, RL & Goble, JC 1980, 'Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man', Journal of Nuclear Medicine, vol. 21, no. 1, pp. 52-58.
Frondoza CG, Trivedi SM, Humphrey RL, Goble JC. Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man. Journal of Nuclear Medicine. 1980;21(1):52-58.
Frondoza, C. G. ; Trivedi, S. M. ; Humphrey, Richard L ; Goble, J. C. / Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man. In: Journal of Nuclear Medicine. 1980 ; Vol. 21, No. 1. pp. 52-58.
@article{cacf0134cac1451fa7d65403d8ad264f,
title = "Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man",
abstract = "[6-14C]arginine, injected intraperitoneally into normal rats, was cleared from the plasma with biphasic decay kinetics. Urinary excretion was efficient (32{\%} of the 25-μCi dose within the first 24 hr) with no preferential tissue retention. In mice, the effective duration of the radiotracer's availability for protein biosynthesis was less than 30 min. When the tracer was administered i.v. to patients with multiple myeloma, it was similarly cleared from the plasma with biphasic kinetics, and was excreted rapidly in the urine (22{\%} of the dose within the first 24 hr). In patients, the guanido-tagged arginine labeled only tumor M component, and the labeling was most intense in patients who had far advanced disease. Estimated radiation dose to humans from a 100-μCi injection was 10 mrads. These studies demonstrate the feasibility of in vivo labeling with [6-14C]arginine, with minimal radiation hazard, thus providing a simple, sensitive, and specific method for monitoring the synthesis of the plasmacytoma M component in patients with multiple myeloma.",
author = "Frondoza, {C. G.} and Trivedi, {S. M.} and Humphrey, {Richard L} and Goble, {J. C.}",
year = "1980",
language = "English (US)",
volume = "21",
pages = "52--58",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Metabolism of guanido-labeled (C-14)arginine in rats, mice, and man

AU - Frondoza, C. G.

AU - Trivedi, S. M.

AU - Humphrey, Richard L

AU - Goble, J. C.

PY - 1980

Y1 - 1980

N2 - [6-14C]arginine, injected intraperitoneally into normal rats, was cleared from the plasma with biphasic decay kinetics. Urinary excretion was efficient (32% of the 25-μCi dose within the first 24 hr) with no preferential tissue retention. In mice, the effective duration of the radiotracer's availability for protein biosynthesis was less than 30 min. When the tracer was administered i.v. to patients with multiple myeloma, it was similarly cleared from the plasma with biphasic kinetics, and was excreted rapidly in the urine (22% of the dose within the first 24 hr). In patients, the guanido-tagged arginine labeled only tumor M component, and the labeling was most intense in patients who had far advanced disease. Estimated radiation dose to humans from a 100-μCi injection was 10 mrads. These studies demonstrate the feasibility of in vivo labeling with [6-14C]arginine, with minimal radiation hazard, thus providing a simple, sensitive, and specific method for monitoring the synthesis of the plasmacytoma M component in patients with multiple myeloma.

AB - [6-14C]arginine, injected intraperitoneally into normal rats, was cleared from the plasma with biphasic decay kinetics. Urinary excretion was efficient (32% of the 25-μCi dose within the first 24 hr) with no preferential tissue retention. In mice, the effective duration of the radiotracer's availability for protein biosynthesis was less than 30 min. When the tracer was administered i.v. to patients with multiple myeloma, it was similarly cleared from the plasma with biphasic kinetics, and was excreted rapidly in the urine (22% of the dose within the first 24 hr). In patients, the guanido-tagged arginine labeled only tumor M component, and the labeling was most intense in patients who had far advanced disease. Estimated radiation dose to humans from a 100-μCi injection was 10 mrads. These studies demonstrate the feasibility of in vivo labeling with [6-14C]arginine, with minimal radiation hazard, thus providing a simple, sensitive, and specific method for monitoring the synthesis of the plasmacytoma M component in patients with multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0018831245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018831245&partnerID=8YFLogxK

M3 - Article

C2 - 7356740

AN - SCOPUS:0018831245

VL - 21

SP - 52

EP - 58

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -